Wang Huiting, Wang Xiaoling, Wang Weiwei, Feng Depeng
Department of Neurology, Liaocheng People's Hospital, No. 67 Dongchang West Road, Liaocheng, 252000, Shandong Province, People's Republic of China.
Department of Neurology, Liaocheng People's Hospital, Shandong University, Jinan, 250012, Shandong, People's Republic of China.
Eur J Med Res. 2024 Dec 19;29(1):600. doi: 10.1186/s40001-024-02184-w.
This retrospective study aimed to investigate the effects of idebenone on cognitive function and serum levels of superoxide dismutase (SOD) and high-sensitivity C-reactive protein (hs-CRP) in individuals with amnestic mild cognitive impairment (aMCI).
Retrospective data were collected from the Neurology outpatient department of Liaocheng People's Hospital from January 2021 to June 2023. Patients with a newly diagnosed aMCI who received treatment were included in the idebenone treatment group. The treatment group took 30 mg of oral idebenone three times a day for 6 months. A control group of 51 MCI patients who did not receive cholinesterase inhibitors or other cognitive-enhancing drugs during the period was selected. Cognitive function assessments and serum Biomarkers were conducted before and after treatment in both groups.
MoCA scores were significantly improved after 6 months of idebenone treatment, and the difference was statistically significant. The delayed recall score was significantly improved, and the difference was statistically significant; The level of SOD increased and the level of high-sensitivity C-reactive protein decreased after the treatment, but there was no significant change in the control group.
The results of this study demonstrate that idebenone treatment significantly improves cognitive function in individuals with aMCI, particularly in the domain of delayed memory. In addition, idebenone reduces the degree of inflammation and oxidative stress and improves antioxidant levels. These findings suggest that idebenone may be a promising intervention for the management of cognitive impairments associated with aMCI.
本回顾性研究旨在探讨艾地苯醌对遗忘型轻度认知障碍（aMCI）患者认知功能以及血清超氧化物歧化酶（SOD）和高敏C反应蛋白（hs-CRP）水平的影响。
收集聊城市人民医院神经内科2021年1月至2023年6月的回顾性数据。将新诊断为aMCI且接受治疗的患者纳入艾地苯醌治疗组。治疗组口服艾地苯醌30毫克，每日3次，共6个月。选取同期51例未接受胆碱酯酶抑制剂或其他认知增强药物治疗的MCI患者作为对照组。两组在治疗前后均进行认知功能评估和血清生物标志物检测。
艾地苯醌治疗6个月后，蒙特利尔认知评估量表（MoCA）评分显著改善，差异有统计学意义。延迟回忆评分显著提高，差异有统计学意义；治疗后SOD水平升高，高敏C反应蛋白水平降低，而对照组无明显变化。
本研究结果表明，艾地苯醌治疗可显著改善aMCI患者的认知功能，尤其是在延迟记忆方面。此外，艾地苯醌可减轻炎症和氧化应激程度，提高抗氧化水平。这些发现提示，艾地苯醌可能是治疗与aMCI相关认知障碍的一种有前景的干预措施。
